Supplementing with beneficial bacteria such as probiotics from an early age is important to protect against autoimmune diseases
Phase 2 trials published in the New England Journal of Medicine showed participants losing an average of 24.2% of their body weight at the 12mg weekly dose over 48 weeks
Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M
7583% achieved 15% 26% of participants on 12 mg achieved 30% weight reduction Cardiometabolic Parameters Improvements in blood pressure, HbA1c, fasting glucose, insulin, LDL-cholesterol 72% of patients with prediabetes achieved normoglycemia Safety Most common adverse events: gastrointestinal (nausea, diarrhea, constipation) , dose-dependent, predominantly mild to moderate Heart rate: slight increase up to week 24, then decrease No severe hypoglycemia, medullary carcinoma, or C-cell hyperplasia Conclusions Retatrutide induced significant, dose-dependent weight reduction of up to 24.2% over 48 weeks